-
ABT-888 (Veliparib) for DNA Repair Studies
2026-08-25
ABT-888 (Veliparib) provides a practical way to suppress PARP1/2 activity while testing chemotherapy, radiation, and DNA damage response dependencies. This guide connects concentration planning, combination assays, MSI and colorectal cancer models, and the reference study’s important negative PARP result.
-
Exercise, Muscle EVs, and Amyloid Clearance in AD
2026-08-25
A 2026 Nature Aging study identifies skeletal muscle-derived extracellular vesicles as a mechanistic link between swimming exercise and improved cognition in Alzheimer’s disease mice. The work connects EV uptake by microglia to disease-associated polarization, amyloid-beta plaque clearance, and a miR-378a-3p–p110α lipid-metabolism pathway, suggesting an exercise-mimicking strategy rather than a simple behavioral association.
-
Persister Lipidomics and Ferroptosis Sensitivity
2026-08-24
Reznik and colleagues show that drug-tolerant persister cancer cells acquire a reversible lipidomic state enriched in ferroptosis-driving diPUFA phospholipids and polyunsaturated fatty acids. Cross-model validation and mitochondrial elimination experiments support a mitochondria-dependent metabolic vulnerability relevant to minimal residual disease research.
-
α-Amanitin A4548: Reliable Transcription Assays
2026-08-24
Learn how α-Amanitin (SKU A4548) can clarify transcription-dependent changes in viability, proliferation, and cytotoxicity assays. This scenario-based guide covers mechanism, assay compatibility, protocol parameters, data interpretation, and practical product-selection criteria supported by product information and published evidence.
-
Angiotensin 1/2 (5-7): Assay Design Guide
2026-08-23
Explore Angiotensin 1/2 (5-7), the H2N-Ile-His-Pro-OH peptide, through a fragment-first framework for renin-angiotensin system research. This guide connects peptide identity, assay controls, cardiovascular interpretation, and emerging SARS-CoV-2 spike-binding evidence.
-
VX-702: A Practical p38α MAPK Inhibitor Workflow
2026-08-22
VX-702 combines selective p38α MAPK inhibition with a practical workflow for cytokine, platelet, arthritis, and cardiac injury studies. This guide connects target-engagement assays to translational models while highlighting solvent control, phospho-signaling interpretation, and troubleshooting strategies.
-
From SA-β-Gal Signal to Senolytic Strategy
2026-08-22
A translational framework for connecting SA-β-Gal detection with senolytic drug discovery, experimental controls, and evidence-based cellular aging research.
-
VX-702: From p38α Blockade to Translational Design
2026-08-21
A mechanistic and translational framework for using VX-702 to study p38α MAPK signaling, cytokine control, inflammatory disease models, platelet biology, and cardiac injury while keeping preclinical evidence in context.
-
Amikacin Disulfate: Designing Better Mechanism Assays
2026-08-20
Amikacin disulfate enables layered studies of ribosomal inhibition, protein interactions, and antibiotic resistance. This guide translates recent lysozyme-binding evidence into practical assay-design decisions without confusing protein complexation with the drug’s primary bacterial target.
-
Ruthenium Red in Mechanostress Calcium Assays
2026-08-20
Ruthenium Red helps separate calcium-dependent signaling from cytoskeletal mechanics in compression-induced autophagy experiments. Its water compatibility and broad membrane activity also support mitochondrial calcium uptake inhibition, sarcoplasmic-reticulum studies, and neurogenic inflammation models when paired with rigorous controls.
-
Tobramycin: In Vitro Workflows and Troubleshooting
2026-08-19
Tobramycin provides a water-based route for studying 30S ribosome inhibition, Gram-negative susceptibility, and resistance-associated shifts in growth. This practical guide translates a classic comparative microtiter study into reproducible assay setup, optimization, and troubleshooting decisions.
-
Roscovitine Workflows for CDK and Cell-Cycle Studies
2026-08-19
Roscovitine, also called Seliciclib, provides a practical way to connect CDK biochemistry with reversible cell-cycle phenotypes and translational tumor models. This workflow emphasizes dose design, orthogonal readouts, washout experiments, and library-aware controls so researchers can distinguish useful pathway engagement from concentration-dependent off-target effects.
-
Dacomitinib Workflows for ErbB Signaling Research
2026-08-18
Build reproducible Dacomitinib assays that connect irreversible pan-HER blockade with receptor signaling, apoptosis, cell-cycle analysis, and resistance biology. The workflow also shows how to evaluate a carefully bounded, exploratory link between ErbB inhibition and the METTL17–mitochondrial ferroptosis axis.
-
MLN2238: Practical Proteasome β5 Assay Workflows
2026-08-18
Build reproducible proteasome-inhibition assays with MLN2238, from solvent handling and β5-focused dose finding to apoptosis, NF-κB, and stress-response readouts. Its reversible activity and strong β5 preference support both hematologic malignancy studies and mechanistic work on proteotoxic stress.
-
EdU Flow Cytometry Assay Kits (Cy5): Lab Guide
2026-08-17
This scenario-based guide explains how SKU K1078 supports reproducible cell cycle S-phase DNA synthesis measurement, multiplexed flow cytometry, and cancer research cell proliferation studies. It covers assay selection, controls, protocol optimization, and interpretation without confusing DNA synthesis with viability.